* shows samples assayed by cycle sequencing or end labelled non-denaturing gel electrophoresis; ‡ shows samples assayed by end labelled non-denaturing gel electrophoresis. 'wt' or '-1' indicates homo/hemizygous, wild type or -1 adenine respectively; 'wt /-1' or 'wt/+1' indicates heterozygous wild type and -1 or +1 adenine respectively.
The MBD4 gene encodes a thymine glycosylase that binds to DNA at methyl-CpG dinucleotide sites and can excise the thymine base at a T.G mismatched basepair resulting from deamination of the methyl-C (Hendrich and Bird, 1998; Bellacosa et al, 1999; Hendrich et al, 1999) . The gene is therefore thought to be an important component of the system that maintains the integrity of methylation patterns throughout the genome, and so silencing of gene transcription. MBD4 contains a polynucleotide stretch of 10 adenines (A 10 ) within one translated exon that we and others have found to be mutated in at least 25% of mismatch repair defective (RER+) colorectal tumours (Bader et al, 1999; Riccio et al, 1999) . The mutation involves either gain or loss of one base and in either case is predicted to cause a premature cessation of translation and production of non-functional protein. It has been suggested from in vitro studies that MBD4 may play a role in the cause of microsatellite instability but this would not be borne out by our observations of mutations seen in vivo for several reasons. Firstly, mutations within the A 10 tract would generate a truncated protein that has lost domains including that shown to interact with MLH1. Secondly, the apparently relatively low frequency of mutation and the strict association of mutation with the RER+ phenotype strongly suggests that MBD4 abnormalities are actually downstream from mismatch repair (MMR) gene defects. Here we report more accurately the frequency and timing of MBD4 mutation in established RER+ sporadic colorectal carcinomas by microdissecting multiple and independent formalin-fixed, paraffin-embedded tumour sections to ensure less than 5% stromal contamination.
MATERIALS AND METHODS
Patients studied were all of those used before in Bader et al (1999) which were microsatellite unstable. 10 µm sections were cut from 10% formalin-fixed paraffin-embedded tissues, dewaxed and stained with eosin. These were aligned with haematoxylin & eosin stained contiguous sections previously scrutinized and marked to identify tumour-rich areas. Selected areas were covered with 10 µl deionized water, scraped with a fresh scalpel blade and transferred into a sterile microfuge tube. The tissue suspension was digested with proteinase K overnight at 42˚C, then extracted once with phenol and chloroform, ethanol precipitated and resuspended in deionized water. Each microdissected site was derived from a section made from an independent paraffin-embedded tumour block, and so represented a region from the same tumour but physically separated from other microdissected sites. PCR amplification and SSCP analyses were done as described in Bader et al (1999) .
RESULTS
Mutations were identified in many of the microdissected sites taken from the same patients as originally assayed from frozen tumour samples. We detected mutations in at least one site in 17 of 19 (89%) primary tumours (see Table 1 ). Some of these, for example case 7 sites b and c, show reduction to homozygosity. In three cases (8, 9 and 15) we found no mutations in microdissected sites despite a mutation in the frozen sample. This was probably a chance occurrence due to different sites of sampling picking up the heterogeneity present in the tumour of these patients. This is easily true for cases 9 and 15 where only three sites were assayed. Figure 1 shows the results for three example cases where whole tissue tumour sample originally gave a negative (apparent lack of mutation) result. Within each tumour there was considerable heterogeneity, implying that the point during clonal development of each tumour when the MBD4 gene sustains mutation may occur late after tumorigenesis has occurred. Theoretically it is possible that a loss or gain of a base could be reverted due to the continuing microsatellite unstable environment, but this is unlikely. Clearly, MBD4 is not mutated in the founder clone of any tumour, nor is it mutated at as early a stage as reported for transforming growth factor β type II receptor (TGFβRII). However 11 of the 17 (65%) cases positive for MBD4 mutation had abnormalities in a majority of sites (more than 50% of all sites tested), suggesting that mutation can be relatively early.
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DISCUSSION
We have found, upon analysis of microdissected sites rather than total tumour tissue, that MBD4 mutations occur in 89% of colorectal cancers. This is significantly more frequent than in previous reports (43% in Bader et al (1999) , 25% in Riccio et al (1999) ). There is, however, a wide range in proportion of mutation positive tumour areas within any one case. Such intratumoral heterogeneity of exonic polynucleotide tracts within sporadic colorectal and other cancers has been documented recently (Abdel-Rahman et al, 1999; Chung et al, 1999; Samowitz and Slattery, 1999) , and implies a late occurrence of mutations in a gene during the progression of the tumour. Thus, MBD4 is not mutated as frequently or as early in tumorigenesis as is the TGFβRII gene (Markowitz et al, 1995) , but mutation is not as rare as for IGFIIR gene (Souza et al, 1996) . It is possible that the observed pattern of MBD4 mutation merely reflects a non-functional consequence of microsatellite instability at this locus. However, mutations in MBD4 downstream of MMR gene defects could still be important such that MBD4 lack of repair of T.G mismatches compounds the MMR defects. The additional mutation load could either promote progression along the tumorigenic pathway, or may help to explain why many RER+ tumours have a better stage-specific prognosis (Bubb et al, 1996; Sankila et al, 1996) . The suggestion that MBD4 could be a tumour suppressor gene remains valid regarding biallelic inactivation. We found in this study frequent reduction to homozygosity, or the presence of +1 and -1 adenine biallelic mutation (for example Figure 1 , case 17), and loss of heterozygosity of neighbouring polymorphic markers has also been reported . The question thus remains, regarding the nature of the proposed biological significance of truncated forms of MBD4 protein at late stages of tumour development. We have hypothesized a dominant negative or gain of function phenotype in cells that are even only heterozygous for the frameshift mutations (Bader et al, 1999 ) and experiments to test this hypothesis are in progress. Hendrich and Bird (1998) have already shown in vitro that C-terminal deleted forms of MBD4 can still efficiently bind to methyl-CpG.
In summary, mutations occur in MBD4 at higher frequencies than originally observed and to a significant degree as biallelic inactivation. It has been previously concluded that MBD4 alterations occur as a downstream event from MMR gene mutation but the results presented here suggest that clonal mutations of MBD4 may nevertheless play a significant role in disease evolution. These observations, together with the proposed function of the protein, suggest intriguingly that MBD4 is important in determining the phenotype of RER+ sporadic colorectal tumours, particularly the later phases of malignancy. 
